Dr. James Karlowsky

Dr. James A. Karlowsky

Professor, Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba

Medical Director, Clinical Microbiology, Shared Health Manitoba

Degrees: B.Sc.[Pharmacy] (Manitoba, 1991), Ph.D. [Medical Microbiology] (Manitoba, 1996)

Postdoctoral Fellowships: Pharmacy (Manitoba, 1998), Medical Microbiology (Iowa, 2005)

Professional Certifications/Awarded Fellowships: D[ABMM] (2005), F[CCM] (2005), F[IDSA] (2007), F[AAM] (2015)

Office address: Department of Clinical Microbiology, Saint Boniface Hospital, 409 Taché Avenue, L4025-10, Winnipeg, Manitoba, R2H 2A6, Canada

Office telephone: (204) 237 2105; E-mail: jkarlowsky@sharedhealthmb.ca

Research Interests:

Antimicrobial resistance; diagnostic clinical microbiology

Recent Publications:

1. Stein M, Tran V, Nichol KA, Lagacé-Wiens PRS, Pieroni P, Adam HJ, Hoban DJ, Turenne C, Walkty A, Normand A-C, Piarroux R, Karlowsky JA. Evaluation of three MALDI-TOF libraries for the identification of filamentous fungi in three hospitals in Manitoba, Canada. Mycoses, 2018; doi: 10.1111/myc.12800.

2. Karlowsky JA, Adam HJ, Golden AR, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG. Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-15. Journal of Antimicrobial Chemotherapy, 2018; doi.org/10.1093/jac/dkx1701.

3. Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem-relebactam against clinical isolates of Gram-negative bacilli isolated in hospital laboratories in the United States – SMART 2016. Antimicrobial Agents and Chemotherapy, 2018, doi:10.1128/AAC.00169-18.

4. Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012-2015. Antimicrobial Agents and Chemotherapy, 2018, doi:10.1128/AAC.02569-17.

5. Karlowsky JA, Adam HJ, Kosowan T, Baxter MR, Nichol KA, Laing NM, Golding GR, Zhanel GG. PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile surveillance study (CAN-DIFF) 2013-2015. Diagnostic Microbiology and Infectious Disease, 2018;91(2):105-111.

6. Karlowsky JA, Lob SH, Kazmierczak KM, Hawser S, Magnet S, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance program. Journal of Antimicrobial Chemotherapy, 2018; doi.org/10.1093/jac/dky107.

7. Zhanel GG, Baxter MR, Adam HA, Olesky M, Sutcliffe J, Karlowsky JA. In vitro activity of eravacycline against 2,213 Gram-negative and 2,424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. Diagnostic Microbiology and Infectious Disease, 2018;91(1):55-62.